CY1108179T1 - Τροποποιημενος παραγοντας viii - Google Patents

Τροποποιημενος παραγοντας viii

Info

Publication number
CY1108179T1
CY1108179T1 CY20081100709T CY081100709T CY1108179T1 CY 1108179 T1 CY1108179 T1 CY 1108179T1 CY 20081100709 T CY20081100709 T CY 20081100709T CY 081100709 T CY081100709 T CY 081100709T CY 1108179 T1 CY1108179 T1 CY 1108179T1
Authority
CY
Cyprus
Prior art keywords
factor viii
modified factor
modified
hemophilia
treatment
Prior art date
Application number
CY20081100709T
Other languages
Greek (el)
English (en)
Inventor
John S Lollar
Original Assignee
Emory University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emory University filed Critical Emory University
Publication of CY1108179T1 publication Critical patent/CY1108179T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/10—Factor VIII, AHF; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Glass Compositions (AREA)
  • Fish Paste Products (AREA)
  • Steroid Compounds (AREA)
CY20081100709T 2000-03-10 2008-07-07 Τροποποιημενος παραγοντας viii CY1108179T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/523,656 US6458563B1 (en) 1996-06-26 2000-03-10 Modified factor VIII
EP01910853A EP1280540B1 (en) 2000-03-10 2001-02-16 Modified factor viii

Publications (1)

Publication Number Publication Date
CY1108179T1 true CY1108179T1 (el) 2014-02-12

Family

ID=24085870

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20081100709T CY1108179T1 (el) 2000-03-10 2008-07-07 Τροποποιημενος παραγοντας viii
CY2016011C CY2016011I2 (el) 2000-03-10 2016-05-10 Τροποποιημενος παραγοντας viii

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY2016011C CY2016011I2 (el) 2000-03-10 2016-05-10 Τροποποιημενος παραγοντας viii

Country Status (35)

Country Link
US (3) US6458563B1 (en:Method)
EP (1) EP1280540B1 (en:Method)
JP (1) JP4044337B2 (en:Method)
KR (1) KR100485525B1 (en:Method)
CN (1) CN1191360C (en:Method)
AT (1) ATE391512T1 (en:Method)
AU (2) AU2001238416B2 (en:Method)
BE (1) BE2016C024I2 (en:Method)
BR (2) BRPI0109131B8 (en:Method)
CA (1) CA2400295C (en:Method)
CY (2) CY1108179T1 (en:Method)
CZ (1) CZ298250B6 (en:Method)
DE (1) DE60133541T2 (en:Method)
DK (1) DK1280540T3 (en:Method)
EE (1) EE05075B1 (en:Method)
ES (1) ES2304379T3 (en:Method)
FR (1) FR16C0016I2 (en:Method)
HU (2) HU227804B1 (en:Method)
IL (2) IL151371A0 (en:Method)
LT (1) LTC1280540I2 (en:Method)
LU (1) LU93049I2 (en:Method)
ME (1) ME00601B (en:Method)
MX (1) MXPA02008798A (en:Method)
NL (1) NL300808I2 (en:Method)
NO (2) NO331935B1 (en:Method)
NZ (1) NZ520799A (en:Method)
PL (1) PL202936B1 (en:Method)
PT (1) PT1280540E (en:Method)
RS (1) RS50364B (en:Method)
RU (1) RU2285724C2 (en:Method)
SI (1) SI1280540T1 (en:Method)
SK (1) SK286205B6 (en:Method)
UA (1) UA75064C2 (en:Method)
WO (1) WO2001068109A1 (en:Method)
ZA (1) ZA200206810B (en:Method)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7560107B2 (en) * 1996-06-26 2009-07-14 Emory University Modified factor VIII
US7615622B2 (en) * 2001-01-12 2009-11-10 University Of Maryland, Baltimore Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor VIII
AU2002337901B2 (en) * 2001-10-05 2008-01-17 Expression Therapeutics Llc Nucleic acid and amino acid sequences encoding high-level expressor factor VIII polypeptides and methods of use
WO2003047507A2 (en) * 2001-11-30 2003-06-12 Emory University Factor viii c2 domain variants
GB0207092D0 (en) 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7498024B2 (en) * 2003-06-03 2009-03-03 Cell Genesys, Inc. Compositions and methods for enhanced expression of immunoglobulins from a single vector using a peptide cleavage site
US7485291B2 (en) * 2003-06-03 2009-02-03 Cell Genesys, Inc. Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
DE602004007924T2 (de) * 2003-06-26 2008-04-10 Merck Patent Gmbh Thrombopoietinproteine mit verbesserten eigenschaften
US20050059023A1 (en) * 2003-09-16 2005-03-17 Cantor Thomas L. Methods and kits for monitoring resistance to therapeutic agents
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
AU2004296768B2 (en) * 2003-12-03 2010-06-24 University Of Rochester Recombinant factor VIII having increased specific activity
WO2005107776A1 (en) * 2004-05-03 2005-11-17 Emory University METHOD OF ADMINISTERING PORCINE B-DOMAINLESS fVIII
WO2005123928A1 (en) * 2004-06-08 2005-12-29 Battelle Memorial Institute Production of human coagulation factor viii from plant cells and whole plants
CN101124331B (zh) * 2004-11-12 2013-04-24 拜尔健康护理有限责任公司 Fvⅲ的位点定向修饰
WO2006063031A2 (en) * 2004-12-06 2006-06-15 Haplomics Allelic variants of human factor viii
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
JP2009518345A (ja) 2005-12-07 2009-05-07 テフニーシェ ウニヴェルジテート ミュンヘン 因子ｖｉｉｉおよび因子ｖｉｉｉ様タンパク質に対する小型ペプチドおよびペプチド模倣物の親和性リガンド
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
ATE474917T1 (de) * 2006-04-11 2010-08-15 Csl Behring Gmbh Verfahren zur erhöhung der in-vivo-gewinnung therapeutischer polypeptide
US7939632B2 (en) * 2006-06-14 2011-05-10 Csl Behring Gmbh Proteolytically cleavable fusion proteins with high molar specific activity
EP1935430A1 (en) * 2006-12-22 2008-06-25 CSL Behring GmbH Modified coagulation factors with prolonged in vivo half-life
EP2097096B1 (en) 2006-12-22 2017-05-31 CSL Behring GmbH Modified coagulation factors with prolonged in vivo half-life
FR2913020B1 (fr) * 2007-02-23 2012-11-23 Biomethodes Nouveaux facteurs viii pour le traitement des hemophiles de type a
EP1988101A1 (en) * 2007-05-04 2008-11-05 Novo Nordisk A/S Improvement of factor VIII polypeptide titers in cell cultures
EP2209908B1 (en) 2007-11-01 2014-09-03 University Of Rochester Recombinant factor viii having increased stability
EP2149603A1 (en) 2008-07-28 2010-02-03 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Factor IX variants with clotting activity in absence of their cofactor and their use for treating bleeding disorders
MX362028B (es) 2009-02-03 2019-01-04 Amunix Pharmaceuticals Inc Polipeptidos recombinantes extendidos y composiciones que comprenden los mismos.
DK3266463T3 (da) 2009-06-09 2024-01-08 Prolong Pharmaceuticals Llc Hæmoglobinsammensætninger
BR112012004094A2 (pt) 2009-08-24 2016-03-08 Amunix Operating Inc composições de fator vii de coagulação e métodos para fazer e usar as mesmas
EP2498804A4 (en) * 2009-11-13 2013-05-08 Puget Sound Blood Ct FACTOR VIII B CELL EPITOPARIANTS WITH REDUCED IMMUNOGENITY
EP3326643B1 (en) 2009-12-06 2021-04-07 Bioverativ Therapeutics Inc. Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
WO2011088391A2 (en) * 2010-01-14 2011-07-21 Haplomics, Inc. Predicting and reducing alloimmunogenicity of protein therapeutics
US9611310B2 (en) 2010-07-09 2017-04-04 Bioverativ Therapeutics Inc. Systems for factor VIII processing and methods thereof
CA2804280A1 (en) 2010-07-09 2012-01-12 Biogen Idec Hemophilia Inc. Chimeric clotting factors
EP2635297B1 (en) 2010-11-05 2019-02-27 Baxalta GmbH A new variant of antihemophilic factor viii having increased specific activity
WO2012094532A1 (en) * 2011-01-05 2012-07-12 Expression Therapeutics, Llc Method and system for suspension cell culture
PL2717898T3 (pl) 2011-06-10 2019-06-28 Bioverativ Therapeutics Inc. Związki o działaniu prokoagulacyjnym i sposoby ich stosowania
TWI764092B (zh) 2011-07-08 2022-05-11 美商百歐維拉提夫治療公司 因子viii嵌合及雜交多肽，及其使用方法
EA028914B1 (ru) 2011-07-25 2018-01-31 Байоджен Хемофилия Инк. Исследования для мониторинга нарушений свертываемости крови
CN102277379B (zh) * 2011-08-18 2013-07-24 中国科学院遗传与发育生物学研究所 表达凝血因子viii的表达载体及其应用
TR201816253T4 (tr) 2012-01-12 2018-11-21 Bioverativ Therapeutics Inc Faktör VIII terapisi almakta olan bireylerde faktör VIII'e karşı immünojenisiteyi azaltmanın yöntemleri.
US11370827B2 (en) 2012-01-12 2022-06-28 Bioverativ Therapeutics Inc. Chimeric factor VIII polypeptides and uses thereof
CN111574632A (zh) 2012-02-15 2020-08-25 比奥贝拉蒂治疗公司 因子viii组合物及其制备和使用方法
EP3549953A1 (en) 2012-02-15 2019-10-09 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
EP2666782A1 (en) * 2012-05-22 2013-11-27 Imnate Sarl Coagulation factor VIII with reduced immunogenicity.
AU2013270683A1 (en) 2012-06-08 2014-12-11 Biogen Ma Inc. Chimeric clotting factors
EP3693000B1 (en) 2012-06-08 2022-03-02 Bioverativ Therapeutics Inc. Procoagulant compounds
WO2014008480A2 (en) 2012-07-06 2014-01-09 Biogen Idec Ma Inc. Cell line expressing single chain factor viii polypeptides and uses thereof
CA2878679A1 (en) 2012-07-11 2014-01-16 Amunix Operating Inc. Factor viii complex with xten and von willebrand factor protein, and uses thereof
HK1212882A1 (zh) 2012-07-25 2016-06-24 Bioverativ Therapeutics Inc. 血液因子的監測分析及其用途
US10391152B2 (en) 2012-10-18 2019-08-27 Bioverativ Therapeutics Inc. Methods of using a fixed dose of a clotting factor
EP2914293A4 (en) 2012-10-30 2016-04-20 Biogen Ma Inc METHOD OF USE OF FVIII POLYPEPTIDE
US10272163B2 (en) 2012-12-07 2019-04-30 The Regents Of The University Of California Factor VIII mutation repair and tolerance induction
EP4223772A3 (en) 2013-02-15 2023-10-18 Bioverativ Therapeutics Inc. Optimized factor viii gene
WO2014144549A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Factor ix polypeptide formulations
TWI629993B (zh) 2013-03-15 2018-07-21 美商生物化學醫療公司 因子ｖｉｉｉ多肽調配物
EP4368194A3 (en) 2013-06-28 2024-07-31 Bioverativ Therapeutics Inc. Thrombin cleavable linker with xten and its uses thereof
EP3875106A1 (en) 2013-08-08 2021-09-08 Bioverativ Therapeutics Inc. Purification of chimeric fviii molecules
EP3033097B1 (en) 2013-08-14 2021-03-10 Bioverativ Therapeutics Inc. Factor viii-xten fusions and uses thereof
CN105848670A (zh) 2013-10-22 2016-08-10 Dbv技术公司 通过诱导对血液因子的耐受治疗血友病的方法
WO2015070014A1 (en) 2013-11-08 2015-05-14 Biogen Idec Ma Inc. Procoagulant fusion compound
WO2015085276A1 (en) 2013-12-06 2015-06-11 Biogen Idec Ma Inc. Population pharmacokinetics tools and uses thereof
EP2881463A1 (en) 2013-12-09 2015-06-10 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Factor IX variants with clotting activity in absence of their cofactor and/or with increased F.IX clotting activity and their use for treating bleeding disorders
SI3091997T1 (sl) 2014-01-10 2022-10-28 Bioverativ Therapeutics Inc. Himerni proteini faktorja VIII in njihova uporaba
NZ722391A (en) 2014-02-04 2022-12-23 Biogen Ma Inc Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications
EP3107561A4 (en) * 2014-02-19 2017-12-20 Bloodworks Factor viii b cell epitope variants having reduced immunogenicity
EP3114138B1 (en) 2014-03-05 2021-11-17 Pfizer Inc. Improved muteins of clotting factor viii
US11008561B2 (en) 2014-06-30 2021-05-18 Bioverativ Therapeutics Inc. Optimized factor IX gene
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
BR112018002150A2 (pt) 2015-08-03 2018-09-18 Bioverativ Therapeutics Inc proteínas de fusão do fator ix e métodos de fabricação e uso das mesmas
PE20231949A1 (es) * 2015-10-30 2023-12-05 Spark Therapeutics Inc VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA
SG10202106307UA (en) 2015-11-13 2021-07-29 Takeda Pharmaceuticals Co Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
EA202092049A1 (ru) 2015-11-13 2020-11-10 Баксалта Инкорпорейтед Вирусные векторы, кодирующие рекомбинантные варианты fviii с повышенной экспрессией для генной терапии гемофилии a
SG11201806398YA (en) 2016-02-01 2018-08-30 Bioverativ Therapeutics Inc Optimized factor viii genes
KR102175878B1 (ko) 2016-06-24 2020-11-06 재단법인 목암생명과학연구소 Fviii 및 vwf 인자를 포함하는 키메라 단백질 및 그 용도
AU2017366709A1 (en) 2016-12-02 2019-07-18 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors
KR20190091292A (ko) 2016-12-02 2019-08-05 바이오버라티브 테라퓨틱스 인크. 응고 인자에 대한 면역 내성 유도 방법
US11633504B2 (en) 2017-05-09 2023-04-25 Emory University Nucleic acids encoding clotting factor variants and their use
BR112020002394A2 (pt) 2017-08-09 2020-07-28 Bioverativ Therapeutics Inc. moléculas de ácidos nucleicos e usos das mesmas
US20210038744A1 (en) 2018-02-01 2021-02-11 Bioverativ Therapeutics Inc. Use of lentiviral vectors expressing factor viii
CA3096038A1 (en) 2018-04-04 2019-10-10 Sigilon Therapeutics, Inc. Implantable particles and related methods
SG11202010767SA (en) 2018-05-18 2020-11-27 Bioverativ Therapeutics Inc Methods of treating hemophilia a
KR20210034013A (ko) 2018-07-16 2021-03-29 박스알타 인코퍼레이티드 발현이 증가된 재조합 fviii 변이체들을 인코딩하는 바이러스 벡터를 이용한 혈우병의 유전적 치료법
EP3833766A1 (en) 2018-08-09 2021-06-16 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof for non-viral gene therapy
UY38389A (es) 2018-09-27 2020-04-30 Sigilon Therapeutics Inc Dispositivos implantables para terapia celular y métodos relacionados
TWI851647B (zh) 2019-01-16 2024-08-11 日商武田藥品工業股份有限公司 用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體
CA3144630A1 (en) 2019-06-19 2020-12-24 Bioverativ Therapeutics Inc. Methods and compositions for treating hemophilia and low bone mineral density with factor viiifc protein
EP3986481A2 (en) 2019-06-20 2022-04-27 Takeda Pharmaceutical Company Limited Method of treatment with viral-based gene therapy
CA3152600A1 (en) 2019-09-30 2021-04-08 Andrew KROETSCH Lentiviral vector formulations
US20230023826A1 (en) 2019-12-12 2023-01-26 Takeda Pharmaceutical Company Limited Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
IL299333A (en) 2020-06-24 2023-02-01 Bioverativ Therapeutics Inc Methods for the purification of viral vectors
TW202246505A (zh) * 2021-03-05 2022-12-01 俄羅斯聯邦商亞那拜恩有限公司 編碼凝血因子ｉｘ蛋白的密碼子優化的核酸及其用途
CN117098996A (zh) * 2021-03-31 2023-11-21 美国血液技术公司 止血测量装置质量控制制剂
US20240269241A1 (en) 2021-06-14 2024-08-15 Takeda Pharmaceutical Company Limited Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
US20230084036A1 (en) 2021-08-23 2023-03-16 Bioverativ Therapeutics Inc. Optimized factor viii genes
AU2022355088A1 (en) 2021-09-30 2024-05-16 Bioverativ Therapeutics Inc. Nucleic acids encoding factor viii polypeptides with reduced immunogenicity
JP2025534659A (ja) 2022-10-11 2025-10-17 シギロン セラピューティクス， インコーポレイテッド 疾患治療のための改変細胞及び移植可能エレメント
WO2025008774A1 (en) 2023-07-05 2025-01-09 Takeda Pharmaceutical Company Limited Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
EP0182448A3 (en) 1984-08-24 1987-10-28 Genetics Institute, Inc. Production of factor viii and related products
AU5772886A (en) 1985-04-12 1986-11-05 Genetics Institute Inc. Novel procoagulant proteins
JPH0387173A (ja) 1987-09-10 1991-04-11 Teijin Ltd ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体
DK162233C (da) 1989-11-09 1992-03-16 Novo Nordisk As Fremgangsmaade til isolering af faktor viii fra blodplasma og pharmaceutisk praeparat indeholdende den saaledes isolerede fator viii
WO1991008216A1 (en) * 1989-12-01 1991-06-13 Genpharm International, Inc. Production of recombinant polypeptides by bovine species and transgenic methods
US5663060A (en) 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII
US6180371B1 (en) * 1996-06-26 2001-01-30 Emory University Modified factor VIII
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US5563045A (en) 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
WO1997003193A1 (en) 1995-07-11 1997-01-30 Chiron Corporation Novel factor viii:c polypeptide analogs with altered metal-binding properties
WO1997003191A1 (en) 1995-07-11 1997-01-30 Chiron Corporation Novel factor viii:c polypeptide analogs comprising factor v domains or subdomains
CN1205221C (zh) * 2000-09-19 2005-06-08 埃默里大学 修饰的凝血因子ⅷ
WO2003047507A2 (en) * 2001-11-30 2003-06-12 Emory University Factor viii c2 domain variants
US7105745B2 (en) * 2002-12-31 2006-09-12 Thomas & Betts International, Inc. Water resistant electrical floor box cover assembly

Also Published As

Publication number Publication date
WO2001068109A1 (en) 2001-09-20
DK1280540T3 (da) 2008-07-14
NL300808I1 (en:Method) 2016-05-18
AU2001238416B2 (en) 2004-09-02
NO20024296D0 (no) 2002-09-09
RU2285724C2 (ru) 2006-10-20
BR122013026957A8 (pt) 2017-02-21
BRPI0109131B1 (pt) 2020-08-25
CA2400295A1 (en) 2001-09-20
SK14392002A3 (sk) 2003-06-03
KR100485525B1 (ko) 2005-04-28
IL151371A (en) 2010-12-30
PT1280540E (pt) 2008-06-09
BE2016C024I2 (en:Method) 2020-01-30
LTC1280540I2 (lt) 2020-05-25
AU3841601A (en) 2001-09-24
US7012132B2 (en) 2006-03-14
ZA200206810B (en) 2003-11-26
SK286205B6 (sk) 2008-05-06
NZ520799A (en) 2004-06-25
ATE391512T1 (de) 2008-04-15
CA2400295C (en) 2012-01-10
CZ298250B6 (cs) 2007-08-01
US6458563B1 (en) 2002-10-01
UA75064C2 (en) 2006-03-15
EP1280540B1 (en) 2008-04-09
IL151371A0 (en) 2003-04-10
BR122013026957A2 (en:Method) 2004-12-07
US20030068785A1 (en) 2003-04-10
CY2016011I1 (el) 2016-10-05
RS50364B (sr) 2009-11-10
KR20020081426A (ko) 2002-10-26
DE60133541D1 (de) 2008-05-21
MEP8209A (en) 2011-12-20
SI1280540T1 (sl) 2008-08-31
CY2016011I2 (el) 2016-10-05
NO331935B1 (no) 2012-05-07
FR16C0016I1 (en:Method) 2016-04-29
US7122634B2 (en) 2006-10-17
EP1280540A4 (en) 2004-11-03
MXPA02008798A (es) 2003-04-25
YU68002A (sh) 2005-11-28
LU93049I2 (fr) 2016-06-27
PL202936B1 (pl) 2009-08-31
ME00601B (me) 2011-12-20
CZ20023346A3 (cs) 2003-01-15
HUP0300586A2 (hu) 2003-06-28
CN1416348A (zh) 2003-05-07
NL300808I2 (nl) 2020-12-21
RU2002124123A (ru) 2004-03-27
BR0109131A (pt) 2004-12-07
NO2016007I1 (no) 2016-05-10
PL359672A1 (en) 2004-09-06
BRPI0109131B8 (pt) 2021-07-06
DE60133541T2 (de) 2009-05-07
HUP0300586A3 (en) 2006-11-28
EP1280540A1 (en) 2003-02-05
ES2304379T3 (es) 2008-10-16
NO2016007I2 (no) 2016-05-10
FR16C0016I2 (fr) 2018-11-02
HK1051004A1 (en) 2003-07-18
HUS1600020I1 (hu) 2016-06-28
EE200200510A (et) 2004-02-16
NO20024296L (no) 2002-11-08
JP2003526358A (ja) 2003-09-09
US20050079584A1 (en) 2005-04-14
EE05075B1 (et) 2008-10-15
HU227804B1 (en) 2012-03-28
CN1191360C (zh) 2005-03-02
JP4044337B2 (ja) 2008-02-06

Similar Documents

Publication Publication Date Title
CY1108179T1 (el) Τροποποιημενος παραγοντας viii
CY1108007T1 (el) Φαρμακευτικες συνθεσεις βοτουλινικης τοξινης
CY1119291T1 (el) Πολυσθενη αντισωματα και χρησεις για αυτα
CY2019029I2 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοi και χρησεις
CY1110462T1 (el) Θεραπεια της ηπατικης ινωσης με αντισωματα εναντιον της ενσωματινης (ιντεγκρινης) αλφα v βητα 6
BRPI0411321A (pt) vetor viral associado a adenovìrus, composição farmacêutica e método para tratar doença de alzheimer, e, uso do vetor viral associado a adenovìrus
TR200202194T2 (tr) Poliglütamik asit-kamptotesin birleşikleri ve hazırlama yöntemleri
MXPA04003333A (es) Remodelado y glicoconjugacion de peptidos.
CY1112862T1 (el) Θραυσματα μονοσθενους αντισωματος χρησιμα ως θεραπευτικα
ATE289640T1 (de) Amidofunktionelle aminopolydiorganosiloxane
EE200300121A (et) CB1 retseptori antagonisti ja sibutramiini kombinatsioon, neid sisaldav farmatseutiline kompositsioon ja kasutamine lihavuse raviks
CY1112458T1 (el) Ενα αντισωμα ειδικο για διαλυτο baff για χρηση στην αντιμετωπιση του καρκινου
DK1487493T3 (da) Konjugater af cytotoksiske midler og biologisk aktive peptider
CY1108281T1 (el) 17-α-υποκατασταθεισα-11-β-υποκατασταθεισα-4-αρυλ και 21-υποκατασταθεισα 19-νορπρεγναδιενοδιονη ως νεοι αντι-προεμμηνορροϊκοι παραγοντες.
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
CY1106156T1 (el) Νεα χρηση βουδεσονιδης και φορμοτepολης
ATE330017T1 (de) Kallikrein gen
CY1112957T1 (el) Μη νευροτοξικοι παραγοντες, οι οποιοι ενεργοποιουν το πλασμινογονο για τη θεραπευτικη αγωγη εγκεφαλικου επεισοδιου
DE69905170T2 (de) Thiazolopyrimidinderivate
DE60321041D1 (de) Antikörper gegen krebsantigen tmeff2 und seine anwendungen
CY1111567T1 (el) Ενδιαμεσα διβενζο (b,f) αζεπινης
ATE359279T1 (de) Moschus-geruchsstoffe
ATE417618T1 (de) Faktor-viii-polypeptide auf hohem expressionsniveau codierende nukleinsäure- und aminosäuresequenzen und verwendungsverfahren
ATE355104T1 (de) Haarbehandlungsmittel
CY1114614T1 (el) Αντιγονα αιμοφιλου ινφλουεντσας και αντιστοιχα dna θραυσματα